1. Gastrointestinal Manifestations among COVID-19 Patients in Bangladesh: A Cross Sectional Study
- Author
-
M M, Khalil, G, Gain, K, Mahbub-Uz-Zaman, M E, Karim, K D, Sarker, D, Akter, M I, Patwary, M R, Chowdhury, M K, Arefin, and F, Ahmed
- Subjects
Adult ,Diarrhea ,Male ,Bangladesh ,SARS-CoV-2 ,Pneumonia, Viral ,COVID-19 ,Middle Aged ,Betacoronavirus ,Cross-Sectional Studies ,Humans ,Female ,Coronavirus Infections ,Pandemics ,Retrospective Studies - Abstract
This study was done to find out the frequency of gastrointestinal manifestations among adult COVID-19 patients in Bangladesh. This descriptive cross sectional retrospective study was conducted from 27 May till 20 June 2020. Data were collected retrospectively from three different hospitals of Dhaka, Bangladesh. Patients were interviewed over telephone and verbal consents were taken. Their demographic and clinical profiles were put in the questionnaires by the investigators themselves. Statistical analysis was done thereafter. Out of 226 patients diagnosed with COVID-19, 145(61.4%) patients had gastrointestinal symptoms. Five of them had none other than gastrointestinal symptoms. Twenty six patients were asymptomatic. Mean age of the patients with were 41.6±14.8 years. Males were affected almost equally as the females (51.72% vs. 48.27%) (Ratio 1.1:1). Anorexia (44.7%) followed by diarrhoea (35%) and nausea (22.6%) were the predominant symptoms. Patients with co-morbidities (74.7%) were more prone to develop GI symptoms. Family members (71.6%) of COVID-19 patients with GI symptomatic patients were more affected than the others. Hospitalizations (77.6%) were more among GI symptomatic patients than the others. Thirty Five percent (35%) patients had diarrhoea. Mean duration of diarrhoea was 2.7±1.7 days with a frequency of were 4±1.8 days per day. Gastrointestinal manifestations are common among patients with COVID-19. Clinicians need to be aware of the GI features amongst COVID-19 patients so that they can be addressed and treated effectively and immediately. Further large scale study is needed to predict the disease outcome among COVID 19 patients with GI symptoms.
- Published
- 2020